No Data
No Data
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
The medical device sector rebounded underwater. Wanfu Biotech rose more than 11%, Yahuilong rose more than 6%, and many stocks such as Chunli Healthcare and Jet Biotech followed suit.
Chunli Medical (01858.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Chunli Healthcare (01858.HK) issued an announcement. The board of directors will hold a board meeting on April 29, 2024 (Monday) to approve (among others) the announcement of the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and consider paying an interim dividend (if any).
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 20
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 2023; 2) the growth of joint products was slightly pressured, and overseas business revenue increased sharply; 3) gross net margin declined slightly, and sales and R&D expenses were steadily declining; 4) operating cash flow performance improved significantly; 5) intensive R&D investment, and the product pipeline was constantly being enriched. (Mainichi Keizai Shimbun)
Chunli Healthcare (688236): Cash flow improved significantly year on year, overseas revenue increased by 82% year on year
The performance was partly affected by collection, and overseas business revenue increased dramatically. In 2023, it achieved revenue of 1,209 million yuan (+0.6%), net profit attributable to mother of 278 million yuan (-9.7%), net profit after deducting non-return to mother of 255 million (-
Chunli Medical (688236) Annual Report Review: Short-term performance is affected by collection, and recovery is expected to accelerate in 24 years
Incident: The company released its annual results report for 23 years, achieved revenue of 1,209 billion yuan (+0.6%) for the whole year, achieved net profit attributable to shareholders of listed companies of 278 million yuan (-9.7%), and realized net profit of 250 million yuan (-9.7%) after deducting non-return to mother
Chunli Medical (688236) 2023 Report Review: Collection affects 23-year performance with high overseas business growth
Matters: The company released its 2023 annual report, with revenue of 1,209 million yuan (+0.58%), net profit to mother of 278 million yuan (-9.72%), and net profit after deducting non-net profit of 255 million yuan (-8.32%).
No Data